ClearPoint Neuro Inc. (CLPT)
Stock Price:
$7.24 USD
-0.06 (-0.82%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
After-hours: $7.29 +0.05 (0.69%) Oct 23, 4:42 PM
Key Info
| Market Cap |
113.90M |
| Revenue (ttm) |
11.73M |
| Net Income (ttm) |
-6.48M |
| Shares Out |
15.73M |
| EPS (ttm) |
-0.42 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$7.24 |
| Previous Close |
$7.30 |
| Change ($) |
-0.06 |
| Change (%) |
-0.82% |
| Day's Open |
7.24 |
| Day's Range |
7.16 - 7.38 |
| Day's Volume |
63,046 |
| 52-Week Range |
2.86 - 8.91 |
More Stats
| Market Cap |
113.90M |
| Enterprise Value |
115.91M |
| Earnings Date (est) |
Nov 10, 2020 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
15.73M |
| Float |
11.54M |
| EPS (basic) |
-0.42 |
| EPS (diluted) |
-0.42 |
| FCF / Share |
-0.38 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
68,769 |
| Short Ratio |
0.66 |
| Short % of Float |
0.60% |
| Beta |
0.77 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
9.71 |
| PB Ratio |
85.71 |
| Revenue |
11.73M |
| Operating Income |
-5.01M |
| Net Income |
-6.48M |
| Free Cash Flow |
-5.92M |
| Net Cash |
-2.02M |
| Net Cash / Share |
-0.13 |
| Gross Margin |
62.94% |
| Operating Margin |
-42.72% |
| Profit Margin |
-55.30% |
| FCF Margin |
-50.46% |
| ROA |
-17.26% |
| ROE |
-157.26% |
| ROIC |
-41.80% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (2)
| Buy |
2 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
Price Target
$10.50*
(45.03% upside)
Low
8.00
Current: $7.24
High
13.00
Target: 10.50
*Average 12-month price target from 2 stock analysts.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 11.22 | 7.35 | 7.38 | 5.75 | 4.59 | 3.60 | 3.93 | 5.06 | 3.82 | 2.67 |
| Revenue Growth | 52.54% | -0.36% | 28.35% | 25.15% | 27.46% | -8.3% | -22.29% | 32.48% | 43.03% | - |
| Gross Profit | 7.38 | 4.92 | 4.48 | 3.11 | 2.61 | 1.68 | 2.51 | 4.50 | 3.16 | 2.65 |
| Operating Income | -4.59 | -5.25 | -6.34 | -7.49 | -8.97 | -5.32 | -7.47 | -3.13 | -5.92 | -9.52 |
| Net Income | -5.54 | -6.16 | -7.17 | -8.07 | -8.45 | -4.52 | -7.09 | -5.88 | -8.31 | -9.45 |
| Shares Outstanding | 13.16 | 10.93 | 7.74 | 2.75 | 1.88 | 1.48 | 1.43 | 1.01 | 0.40 | 0.17 |
| Earnings Per Share | -0.42 | -0.56 | -0.93 | -2.93 | -4.48 | -3.06 | -4.80 | -6.00 | -20.80 | -56.00 |
| Operating Cash Flow | -2.85 | -4.63 | -5.99 | -5.82 | -8.64 | -7.25 | -7.78 | -7.43 | -6.24 | -7.71 |
| Capital Expenditures | -0.16 | -0.06 | -0.03 | -0.10 | -0.08 | -0.05 | -0.07 | -0.13 | -0.03 | -0.06 |
| Free Cash Flow | -3.01 | -4.69 | -6.02 | -5.92 | -8.71 | -7.30 | -7.85 | -7.56 | -6.27 | -7.77 |
| Cash & Equivalents | 5.70 | 3.10 | 9.29 | 3.32 | 5.41 | 9.24 | 3.52 | 1.62 | 0.15 | - |
| Total Debt | 2.46 | 3.48 | 4.92 | 4.49 | 7.95 | 7.69 | 8.42 | 6.53 | 14.43 | - |
| Net Cash / Debt | 3.23 | -0.38 | 4.37 | -1.18 | -2.54 | 1.55 | -4.91 | -4.91 | -14.29 | - |
| Assets | 11.93 | 7.86 | 13.90 | 7.40 | 9.94 | 13.39 | 7.87 | 5.55 | 3.03 | - |
| Liabilities | 7.34 | 6.35 | 8.07 | 8.16 | 11.92 | 13.49 | 14.71 | 13.42 | 24.87 | - |
| Book Value | 4.59 | 1.51 | 5.83 | -0.76 | -1.98 | -0.10 | -6.83 | -7.87 | -21.84 | - |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
ClearPoint Neuro Inc. |
| Country |
United States |
| Employees |
49 |
| CEO |
Joseph Michael Burnett |
Stock Information
| Ticker Symbol |
CLPT |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Devices |
| Unique Identifier |
NASDAQ: CLPT |
Description
ClearPoint Neuro operates as a medical device company primarily in the United States. The company develops and commercializes platforms for performing minimally invasive surgical procedures in the brain and heart under direct, and intra-procedural magnetic resonance imaging (MRI) guidance. It offers ClearPoint system, a neuro-navigation system designed for insertion of catheters, electrodes, and laser fibers to treat various neurological diseases and conditions, as well as for performing biopsies. In addition, the company's product pipeline includes ClearTrace system, a product candidate designed to allow catheter-based minimally invasive procedures in the heart to be performed in an MRI suite. The company has a license agreements with The Johns Hopkins University; development agreement with Mayo Clinic to design and develop MRI-guided therapies for stroke; and a collaborative license and co-development agreement with Clinical Laserthermia Systems AB. The company was formerly known as MRI Interventions, Inc. and changed its name to ClearPoint Neuro, Inc. in February 2020. ClearPoint Neuro, Inc. was founded in 1998 and is headquartered in Irvine, California.